US OptionsDetailed Quotes
GERN240830C4500
- 0.15
- -0.07-31.82%
15min DelayClose Aug 30 16:00 ET
0.20High0.08Low
0.15Open0.22Pre Close55 Volume316 Open Interest4.50Strike Price819.00Turnover0.00%IV-2.11%PremiumAug 30, 2024Expiry Date0.25Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.84Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Geron Stock Discussion
折扣价赶快买！
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron (GERN.US)$
https://stockregion.app/p/investment-bank-initiates-overweight
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline (GSK.US)$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
This could get interesting considering the short stats.
2.85 days to cover. 10.46% short floats.
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This ...
No comment yet